SCHEMBL8959744

SCHEMBL8959744

O=C(O)c1cc2c(C(F)(F)F)c(F)ccc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 3/20 0.49
HSD17B10 Q99714 3/20 0.49
LMNA P02545 2/20 0.49
HPGD P15428 2/20 0.47
CYP2C19 P33261 2/20 0.47
PDPK1 O15530 1/20 0.47
TSHR P16473 1/20 0.47
NFKB1 P19838 1/20 0.47
APEX1 P27695 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
IDO1 P14902 5/20 0.47
TDO2 P48775 5/20 0.47
EIF4A3 P38919 1/20 0.47
RHEB Q15382 5/20 0.45
NGFR P08138 1/20 0.44
GRIN1 Q05586 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
F7 P08709 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22717972 0.82 FLT3 (0.43) KDM4EALDH1A1HSD17B10LMNAHPGD
SCHEMBL29974441 0.80 KDM4E (0.54) KDM4EALDH1A1HSD17B10LMNAHPGD
SCHEMBL10085352 0.80 KDM4E (0.54) KDM4EALDH1A1HSD17B10LMNAHPGD
SCHEMBL8959852 0.79 KDM4E (0.51) KDM4EALDH1A1HSD17B10LMNAHPGD
SCHEMBL10003246 0.79 MEN1 (0.36) KDM4EALDH1A1HSD17B10LMNACYP2C19
SCHEMBL9229419 0.78 KMT2A (0.40) KDM4EALDH1A1HSD17B10HPGDTDP1
SCHEMBL22620683 0.78 KDM4E (0.51) KDM4EALDH1A1HSD17B10LMNAHPGD
SCHEMBL3100612 0.78 HRH4 (0.60) KDM4EALDH1A1HSD17B10LMNAHPGD
SCHEMBL6161388 0.78 DAO (0.58) KDM4EALDH1A1HSD17B10LMNAHPGD
SCHEMBL29425136 0.78 DAO (0.58) KDM4EALDH1A1HSD17B10LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3976617-B1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2025-04-23 EP disclosed
US-20220348592-A1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2022-11-03 US disclosed
EP-3976617-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-04-06 EP disclosed
CN-113906028-A Fused heterocyclic derivatives 爱尔兰詹森科学公司 2022-01-07 CN disclosed
WO-2020243135-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2020-12-03 WO disclosed
WO-2020243135-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2020-12-03 WO disclosed
CN-1061341-C 1-amino-ethylindole-derivatives HOFFMANN LA ROCHE (CH) 2001-01-31 CN disclosed
US-5494928-A FOR CENTRAL NERVOUS SYSTEM DISORDERS, BLOCKING SEROTONIN RECEPTORS, ANTIDEPRESSANTS HOFFMANN-LA ROCHE INC. (US) 1996-02-27 US disclosed
CN-1105988-A 1-amino-ethylindole-derivatives HOFFMANN LA ROCHE (CH) 1995-08-02 CN disclosed
EP-0655440-A2 1-Aminoethylindoles F. HOFFMANN-LA ROCHE AG (CH) 1995-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348592-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 KDM4E 3515/4885ALDH1A1 2000/4885HSD17B10 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.